Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.

导出 OA

翻译打印收藏纠错

第一作者： Caitlin M,Stewart

第一单位： Diagnostic Molecular Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

作者： Caitlin M,Stewart ^[1] ; Laure,Michaud ^[2] ; Karissa,Whiting ^[3] ; Reiko,Nakajima ^[3] ; Chelsea,Nichols ^[4] ; Stephanie,De Frank ^[4] ; Paul A,Hamlin ^[4] ; Matthew J,Matasar ^[4] ; John F,Gerecitano ^[4] ; Pamela,Drullinsky ^[4] ; Audrey,Hamilton ^[4] ; David,Straus ^[4] ; Steven M,Horwitz ^[4] ; Anita,Kumar ^[4] ; Craig H,Moskowitz ^[4] ; Alison,Moskowitz ^[4] ; Andrew D,Zelenetz ^[4] ; Jurgen,Rademaker ^[2] ; Gilles,Salles ^[4] ; Venkatraman,Seshan ^[3] ; Heiko,Schöder ^[2] ; Anas,Younes ^[4] ; Dana W Y,Tsui ^[5] ; Connie Lee,Batlevi ^[5]

作者单位： Diagnostic Molecular Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. ^[1] Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. ^[2] Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. ^[3] Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ^[4] Diagnostic Molecular Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. leec@mskcc.org danalhe3@gmail.com. ^[5]